drugset / Trial / NCT02499328
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
RandomizedParallel-groupOpen-labelTreatment
Summary
This multicentre, open-label, Phase 1b/2 study is designed as a 2 part study consisting of a dose-escalation, safety run-in Part A and a dose-expansion Part B
Timeline
- Start
- 2015-08-06
- Primary completion
- 2020-02-28
- Completion
- 2025-10-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD5069 | Small molecule | — | — |
| Subject | Danvatirsen | Antisense oligonucleotide | — | — |
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Subject | Tremelimumab | Monoclonal antibody | — | — |